We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What Analyst Projections for Key Metrics Reveal About Merit Medical (MMSI) Q1 Earnings
Read MoreHide Full Article
Wall Street analysts expect Merit Medical (MMSI - Free Report) to post quarterly earnings of $0.75 per share in its upcoming report, which indicates a year-over-year decline of 2.6%. Revenues are expected to be $352.33 million, up 8.9% from the year-ago quarter.
The consensus EPS estimate for the quarter has undergone a downward revision of 0.1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Merit Medical metrics that are commonly monitored and projected by Wall Street analysts.
Analysts' assessment points toward 'Revenue- Cardiovascular- Peripheral Intervention' reaching $141.95 million. The estimate points to a change of +5.4% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenue- Cardiovascular- Cardiac Intervention' will likely reach $98.79 million. The estimate suggests a change of +8.9% year over year.
Based on the collective assessment of analysts, 'Revenue- Endoscopy' should arrive at $17.89 million. The estimate suggests a change of +76.5% year over year.
Analysts expect 'Revenue- Cardiovascular- OEM' to come in at $43.84 million. The estimate points to a change of +11.6% from the year-ago quarter.
It is projected by analysts that the 'Revenue- Cardiovascular' will reach $334.45 million. The estimate indicates a year-over-year change of +6.7%.
The consensus among analysts is that 'Revenue- Cardiovascular- Custom Procedural Solutions' will reach $49.74 million. The estimate points to a change of +1.9% from the year-ago quarter.
The consensus estimate for 'Geographic Sales- United States' stands at $208.66 million. The estimate suggests a change of +12.1% year over year.
The average prediction of analysts places 'Geographic Sales- International' at $143.33 million. The estimate suggests a change of +4.3% year over year.
Over the past month, shares of Merit Medical have returned -10.6% versus the Zacks S&P 500 composite's -5.6% change. Currently, MMSI carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
What Analyst Projections for Key Metrics Reveal About Merit Medical (MMSI) Q1 Earnings
Wall Street analysts expect Merit Medical (MMSI - Free Report) to post quarterly earnings of $0.75 per share in its upcoming report, which indicates a year-over-year decline of 2.6%. Revenues are expected to be $352.33 million, up 8.9% from the year-ago quarter.
The consensus EPS estimate for the quarter has undergone a downward revision of 0.1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Merit Medical metrics that are commonly monitored and projected by Wall Street analysts.
Analysts' assessment points toward 'Revenue- Cardiovascular- Peripheral Intervention' reaching $141.95 million. The estimate points to a change of +5.4% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenue- Cardiovascular- Cardiac Intervention' will likely reach $98.79 million. The estimate suggests a change of +8.9% year over year.
Based on the collective assessment of analysts, 'Revenue- Endoscopy' should arrive at $17.89 million. The estimate suggests a change of +76.5% year over year.
Analysts expect 'Revenue- Cardiovascular- OEM' to come in at $43.84 million. The estimate points to a change of +11.6% from the year-ago quarter.
It is projected by analysts that the 'Revenue- Cardiovascular' will reach $334.45 million. The estimate indicates a year-over-year change of +6.7%.
The consensus among analysts is that 'Revenue- Cardiovascular- Custom Procedural Solutions' will reach $49.74 million. The estimate points to a change of +1.9% from the year-ago quarter.
The consensus estimate for 'Geographic Sales- United States' stands at $208.66 million. The estimate suggests a change of +12.1% year over year.
The average prediction of analysts places 'Geographic Sales- International' at $143.33 million. The estimate suggests a change of +4.3% year over year.
View all Key Company Metrics for Merit Medical here>>>
Over the past month, shares of Merit Medical have returned -10.6% versus the Zacks S&P 500 composite's -5.6% change. Currently, MMSI carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>